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Endocrine therapy for breast cancer consists of a
variety of both medical and surgical ablative treatment
modalities, but ablative therapy has been almost com-
pletely replaced by medical treatments. Most endocrine
therapies have more than one endocrine eﬀect, frequently
together with direct growth-inhibitory actions. In the past
two decades, the number of endocrine agents available
has drastically increased. Some novel approaches to en-
docrine therapies for breast cancer are the less toxic and
more potent aromatase inhibitors, oestradiol receptor
modulators (SERMS) and downregulators (‘‘pure anti-
oestrogens’’), luteinising hormone-releasing hormone
(LHRH) analogues, growth factor receptor antibodies
and inhibitors of growth factor signal transduction. The
role of progesterone receptor (PgR) modulators is, as yet,
unclear. In postmenopausal metastatic breast cancer,
aromatase inhibitors have replaced tamoxifen as ﬁrst-line
endocrine treatment, but the optimal sequence of (po-
tential) endocrine therapies is still debated. In pre-
menopausal metastatic breast cancer, combination
treatment with a LHRH agonist and tamoxifen is most
eﬀective, but tamoxifen might also be replaced in this
subgroup by an aromatase inhibitor in the near future. A
number of cell biological factors predict resistance to ta-
moxifen treatment, and these factors will probably diﬀer
with respect to other endocrine therapies. Tumour re-
sistance to endocrine therapy can be modiﬁed by anti-
growth factor therapy. Therefore, many trials with the
aim of improving the results of endocrine therapy have
still to be performed.
1. Introduction
In 1896, endocrine therapy of breast cancer was ﬁrst
applied by means of surgical oophorectomy. Since then,
a lot of surgical, radiotherapeutical and, especially,
medical systemic therapies have been developed, such as
adrenalectomy, hypophysectomy, ovarian or pituitary
irradiation, androgens, synthetic oestrogens, high-dose
progestins, aromatase inhibitors, LHRH-agonists, anti-
progestins, pure anti-oestrogens, new speciﬁc oestrogen
receptor modulators (SERMs) and anti-growth factor
therapies. Previously, endocrine treatment was given to
all patients, but during the last 15 years this treatment is
being increasingly restricted to patients with hormone
receptor (oestrogen receptor (ER), PgR-positive tu-
mours) or with unknown receptor status but with a
long-term disease-free interval. Until recently, tamoxifen
was the standard ﬁrst-line endocrine therapy for breast
cancer, but now a number of other treatment options
are available.
2. Predictive factors
Overall, an objective response or long-term stable
disease (> 6 months) occur in approximately 50–70% of
patients with ER-positive tumours. However, a sig-
niﬁcant number of patients have tumours that are re-
sistant to endocrine therapy. Ultimately, all patients
with metastatic disease will develop resistance to hor-
monal therapy. ER, PgR, pS2 and tissue plasminogen
activator (tPA) predict a favourable response to ta-
moxifen treatment. By contrast, increased expression of
urokinase-plasminogen activator (uPA), plasminogen
activator inhibitor-1 (PAI-1), urokinase plasminogen
activator receptor (uPAR), p53, epidermal growth fac-
tor receptor (EGFR), HER2/neu, vascular endothelial
growth factor (VEGF) and mutations in TP53 are as-
sociated with a worse response to endocrine treatment
[1]. Recently, it has been shown that gene expression
proﬁles and gene methylation status measured using
micro-array analyses can also predict the response to
endocrine therapy.E-mail address: j.g.m.klijn@erasmusmc.nl.
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3. Premenopausal metastatic breast cancer
Options for endocrine therapy are surgical oophor-
ectomy, medical castration by LHRH analogues, or
tamoxifen. Combined endocrine treatment with a
LHRH-agonist plus tamoxifen is currently the ﬁrst
choice of treatment because this combination appears to
be signiﬁcantly superior to single endocrine therapy with
respect to response rate, progression-free survival and
overall survival [2,3]. Replacing tamoxifen by anastro-
zole in combination with goserelin caused a stronger
suppression (98%) of plasma oestrogen concentrations
i.e. from 224 to 5 pmol/l in contrast to 24 pmol/l (89%
reduction) during treatment with goserelin plus tamoxi-
fen [4]. A randomised phase II study by Milla-Santos
et al. [5], comparing the eﬃcacy of goserelin plus ana-
strozole with that of goserelin plus tamoxifen showed
superior results for the combination of goserelin plus
anastrozole with respect to the response rate (80% versus
53%), median duration of response (12.1 versus 8.3
months) and median survival (18.9 versus 14.3 months).
However, conﬁrmative studies are needed.
4. Postmenopausal metastatic breast cancer
New potent and selective aromatase inhibitors and
inactivators have now replaced tamoxifen as ﬁrst-line
therapy for metastatic breast cancer [6–9]. They appear
to be more eﬀective than tamoxifen in patients with low
ER tumour levels, ER+ PgR– tumours and ER+ HER2/
neu+ tumours [10]. The third generation drugs, ana-
strozole, letrozole and exemestane, are used in many
trials and in daily clinical practice.
Another new interesting compound is the ‘pure anti-
oestrogen’, fulvestrant (Faslodex) [11–13]. Fulvestrant
appears to be at least as eﬀective as anastrozole in pa-
tients with progressive disease after ﬁrst-line treatment
with tamoxifen. In the ﬁrst-line setting, treatment with
fulvestrant showed equal anti-tumour eﬃcacy when
compared with tamoxifen. In the adjuvant setting Ar-
imidex, tamoxifen, alone or in combination (ATAC)-
trial, the combination treatment of tamoxifen and
anastrozole appeared to be less eﬀective than single
treatment with anastrozole alone due to the oestrogen
agonistic actions of tamoxifen in the presence of low
plasma oestrogen levels. In view of the fact that fulves-
trant lacks oestrogenic activities, but downregulates ER
and PgR, the combination of fulvestrant with an ar-
omatase inhibitor might improve the results of endo-
crine treatments for breast cancer.
Finally, treatment with high-dose progestins, andro-
gens and high-dose oestrogens are still valuable as 3rd–
5th-line treatment modalities in patients with hormone-
sensitive disease after treatment with anti-oestrogens
and aromatase inhibitors. The role of PgR modulators
(anti-progestins) is unclear, but this category of drugs
remains interesting [14].
5. Biologicals
Overexpression of HER2/neu, EGFR and VEGF are
frequently associated with hormone-resistant tumours.
Antibodies against (receptors of) these growth factors or
signal transduction inhibitors of their pathways can re-
duce tumour growth in preclinical experimental tumour
models and in patients with metastatic disease. Single
ﬁrst-line treatment with Herceptin (anti-HER2/neu) can
induce tumour remission in up to 40% of patients with
HER2/neu-positive tumours, but other anti-growth
factor therapies, such as geﬁtinib (Iressa; ZD1839) ap-
peared to be less eﬀective when used as single treat-
ments. However, targeting both growth factor and ER
pathways may achieve greater tumour inhibition than
targeting either pathway alone, as has been shown in
in-vitro studies.
6. Conclusions
The most important treatment modality in patients
with ER+ tumours is endocrine therapy. Chemotherapy
is most important in patients with ER– HER2– tumours
and in patients with ER– HER2+ tumours Herceptin is
the treatment of choice. Combination therapies of bio-
logicals with conventional standard endocrine and che-
motherapies [15] and the combination of diﬀerent
biological therapies are most promising strategies.
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